Financial Gravity Companies Inc. Purchases New Position in Merck & Co., Inc. (NYSE:MRK)

Financial Gravity Companies Inc. bought a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 862 shares of the company’s stock, valued at approximately $66,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Contravisory Investment Management Inc. lifted its holdings in Merck & Co., Inc. by 186.4% during the fourth quarter. Contravisory Investment Management Inc. now owns 653 shares of the company’s stock valued at $50,000 after purchasing an additional 425 shares in the last quarter. Arlington Partners LLC lifted its holdings in shares of Merck & Co., Inc. by 93.5% in the fourth quarter. Arlington Partners LLC now owns 828 shares of the company’s stock worth $63,000 after buying an additional 400 shares in the last quarter. Advisors Preferred LLC purchased a new position in shares of Merck & Co., Inc. in the fourth quarter worth $66,000. Quantamental Technologies LLC purchased a new position in shares of Merck & Co., Inc. in the fourth quarter worth $109,000. Finally, Legacy Bridge LLC purchased a new position in shares of Merck & Co., Inc. in the fourth quarter worth $110,000. Institutional investors own 73.46% of the company’s stock.

MRK has been the topic of several research analyst reports. Zacks Investment Research raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $93.00 target price on the stock in a report on Monday, April 1st. Cantor Fitzgerald reaffirmed a “buy” rating and set a $95.00 price target on shares of Merck & Co., Inc. in a research note on Friday, March 29th. Argus upped their price target on shares of Merck & Co., Inc. to $95.00 and gave the company a “buy” rating in a research note on Wednesday, February 20th. ValuEngine downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, BMO Capital Markets reaffirmed a “hold” rating on shares of Merck & Co., Inc. in a research note on Tuesday, February 19th. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Merck & Co., Inc. presently has a consensus rating of “Buy” and a consensus price target of $78.74.

In other Merck & Co., Inc. news, VP Rita A. Karachun sold 64,662 shares of the stock in a transaction dated Thursday, February 14th. The shares were sold at an average price of $78.96, for a total transaction of $5,105,711.52. Following the completion of the sale, the vice president now directly owns 53,327 shares of the company’s stock, valued at $4,210,699.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Merck & Co., Inc. purchased 4,121,683 shares of the firm’s stock in a transaction on Monday, April 8th. The shares were purchased at an average cost of $16.00 per share, with a total value of $65,946,928.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 1,094,632 shares of company stock valued at $87,840,652. 0.32% of the stock is owned by insiders.

NYSE:MRK traded down $0.73 during mid-day trading on Friday, reaching $73.19. The company’s stock had a trading volume of 31,267,836 shares, compared to its average volume of 11,405,758. Merck & Co., Inc. has a 1 year low of $56.26 and a 1 year high of $83.85. The firm has a market cap of $197.33 billion, a PE ratio of 16.86, a price-to-earnings-growth ratio of 1.78 and a beta of 0.63. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.17 and a quick ratio of 0.92.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Friday, February 1st. The company reported $1.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.01. Merck & Co., Inc. had a net margin of 14.71% and a return on equity of 36.83%. The company had revenue of $11 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same period in the prior year, the firm earned $0.98 earnings per share. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Sell-side analysts anticipate that Merck & Co., Inc. will post 4.65 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 5th. Investors of record on Friday, March 15th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 3.01%. The ex-dividend date of this dividend was Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 50.69%.

COPYRIGHT VIOLATION NOTICE: “Financial Gravity Companies Inc. Purchases New Position in Merck & Co., Inc. (NYSE:MRK)” was posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/862-shares-in-merck-co-inc-mrk-acquired-by-financial-gravity-companies-inc.html.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Article: How prevalent are 12b-1 fees?

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.